What question did this study set out to answer?

To provide updated guidance on optimizing treatment for heart failure with reduced ejection fraction based on recent evidence.

April 23, 2026Journal of the American College of Cardiology835 citations

Ver artículo completo

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

TMThomas M. Maddox JJJames L. Januzzi LALarry A. Allen

Puntos clave

To provide updated guidance on optimizing treatment for heart failure with reduced ejection fraction based on recent evidence.
Reviewed 2017 ACC expert consensus and updated recommendations in light of new research findings.
Focused on 10 key questions regarding treatment strategies for heart failure with reduced ejection fraction.
Identified new therapeutic interventions that enhance patient outcomes.
Clarified the role of ejection fraction in treatment decision-making for heart failure.
Highlighted evidence-based updates to existing treatment pathways.

Resumen

No se publicó un resumen junto con este documento; las guías de sociedades, las vías de consenso y las declaraciones científicas suelen difundirse sin él. Consulte los Puntos Clave y el PDF enlazado para ver el contenido completo.

Expert Takes4 quotes

1/4

“Relative to an ACE inhibitor and a beta-blocker alone, optimal implementation of the current guideline-directed medical therapies can extend medical survival by more than 6 years.”

Gregg C. Fonarow, Chief of cardiology, University of California Los AngelesUniversity of California, Los Angelesauto_pipelineView source

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Maddox et al. (Wed,) studied this question.

synapsesocial.com/papers/69e98f9e72ff25a8e3dbc078 https://doi.org/https://doi.org/10.1016/j.jacc.2020.11.022

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo